Antibacterial drug, Recarbrio, receives FDA approval for treatment of complicated UTIs and intra-abdominal infections

The U.S. Food and Drug Administration has approved Recarbrio (imipenem, cilastatin and relebactam), an antibacterial drug product to treat adults with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI). "The FDA remains focused on facilitating the development of safe and effective new antibacterial drugs to give patients more options to fight serious infections," ["]

The post Antibacterial drug, Recarbrio, receives FDA approval for treatment of complicated UTIs and intra-abdominal infections appeared first on Outbreak News Today.